France-based Sensorion's Seliforant has failed to meet the primary endpoint in the phase 2b proof-of-concept trial intended to treat acute unilateral vestibulopathy (AUV), it was reported yesterday.
The product is an orally available small molecule histamine type four receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the product was safe and well tolerated, but did not achieve the primary endpoint of vertigo intensity. The primary endpoint was measured by the area under the curve of the vertigo intensity visual analogue scale in standing position during the four treatment days, with eight post baseline evaluations.
The randomised, double-blind, placebo-controlled study included three parallel arms and evaluated the efficacy and safety of SENS-111 histamine H4 receptor antagonist. The company hired 105 patients in the phase 2b trial at the centres in Europe, Israel, South Korea and the US with a 1:1:1 randomisation ratio. The patients were stratified by duration of vertigo before treatment.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients